Am I still lactose tolerant? - Lactose Gene Therapy Update

The Thought Emporium

The Thought Emporium

12 min, 24 sec

A detailed update on the gene therapy experiment aimed at curing lactose intolerance, explaining the initial success, subsequent wear-off, and future improvements.

Summary

  • The speaker initially used a home-brewed genetically modified virus to cure his lactose intolerance, achieving 18 months of tolerance.
  • As the effect wore off, he discussed the original study on rats, and his own results, which aligned with the study's findings.
  • He then compared the old gene therapy method using AAVs with a new, potentially safer and cheaper non-viral method using chitosan for DNA delivery.
  • The new DNA plasmid is designed to be human-compatible, avoiding immune system reactions and increasing the duration of effectiveness.
  • An appeal for community feedback and testing in cell culture, not humans, was made along with sharing the DNA file on GitHub.

Chapter 1

Introduction to the Gene Therapy Experiment

0:09 - 1 min, 16 sec

The speaker recounts his successful experiment to cure lactose intolerance using a genetically modified virus.

The speaker recounts his successful experiment to cure lactose intolerance using a genetically modified virus.

  • The speaker used a genetically modified virus to cure his lactose intolerance, which was effective for a long time.
  • He had become lactose intolerant in high school due to the inability to produce the enzyme lactase.

Chapter 2

Success and Longevity of the Treatment

1:26 - 1 min, 27 sec

The speaker describes the duration of the lactose intolerance treatment's effectiveness and its gradual wear-off.

The speaker describes the duration of the lactose intolerance treatment's effectiveness and its gradual wear-off.

  • The treatment remained effective for about 18 months before the speaker had to start taking lactase pills again.
  • The experiment was based on a study done on rats, and the speaker's results matched the study's six-month effectiveness.

Chapter 3

Comparison of Old and New DNA Plasmids

2:52 - 6 min, 19 sec

The speaker explains the differences between the old virus-based and the new non-viral method for lactase gene delivery.

The speaker explains the differences between the old virus-based and the new non-viral method for lactase gene delivery.

  • The original therapy used AAV for delivery, while the new design uses chitosan for cheaper and safer delivery.
  • The new plasmid features human lactase to avoid immune response and a human promoter for consistent gene expression.
  • An S/MAR sequence was added to the new plasmid to potentially increase the duration of the treatment's effectiveness.

Chapter 4

Community Involvement and Safety Measures

9:11 - 3 min, 10 sec

The speaker invites community contributions to the project and emphasizes safety and proper testing protocols.

The speaker invites community contributions to the project and emphasizes safety and proper testing protocols.

  • The DNA file has been uploaded to GitHub for community feedback, with a request to share any synthesized DNA with the speaker.
  • The speaker cautions against self-testing and outlines the importance of cell culture testing before considering human trials.